The patent describes the extraction and standardization of stable doses of psychedelic compounds and strengthens Filament’s industry-leading IP portfolio VANCOUVER, BC, Aug. 17, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued an eighth patent…


Previous articleReunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022
Next articleSmall Pharma Announces TSXV Approval of Normal Course Issuer Bid